ArticleCommunications biology2026
Parallel CRISPR screens reveal pathways controlling the cell surface levels of the attractant receptor FPR1.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Chemoattractants generate strong chemotactic and cytotoxic responses in immune cells by activating cognate receptors. Cell surface receptor levels control sensitivity, which is critical for achieving effective responses without excessive inflammation. The surface levels of the attractant receptor FPR1 are controlled through a balance of delivery and removal, which responds to receptor activation and other stimuli. While this regulation is critical for appropriate responses, the underlying mechanisms remain unclear, including the roles of classic endocytosis regulators. We address these questions using both focused and genome-scale approaches. We find that the receptor kinase GRK6 acts in parallel with GRK2 and GRK3 to trigger internalization, and that internalization uses a β-arrestin-independent pathway, as well as pathways involving β-arrestin1 and 2. Moreover, we use an integrated analysis of two parallel CRISPR/Cas9 screens to classify regulators of FPR1 biogenesis, surface expression, recycling, and endocytosis. We identify the formin mDia1 and the small GTPase ARF6 as specific regulators of FPR1 internalization, which we confirm using chemical inhibitors in primary human neutrophils. Finally, we find that ARF6 contributes to the β-arrestin-independent pathway. Together, our results provide a systems overview of the control of FPR1 surface levels and offer insights into alternative endocytosis mechanisms used by chemoattractant receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.